323 related articles for article (PubMed ID: 24336158)
21. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
Abe A; Minaguchi T; Ochi H; Onuki M; Okada S; Matsumoto K; Satoh T; Oki A; Yoshikawa H
Hum Pathol; 2013 Feb; 44(2):199-207. PubMed ID: 22955107
[TBL] [Abstract][Full Text] [Related]
22. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
Su YF; Tsai EM; Chen CC; Wu CC; Er TK
Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
[TBL] [Abstract][Full Text] [Related]
23. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
[TBL] [Abstract][Full Text] [Related]
24. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Chandler RL; Damrauer JS; Raab JR; Schisler JC; Wilkerson MD; Didion JP; Starmer J; Serber D; Yee D; Xiong J; Darr DB; Pardo-Manuel de Villena F; Kim WY; Magnuson T
Nat Commun; 2015 Jan; 6():6118. PubMed ID: 25625625
[TBL] [Abstract][Full Text] [Related]
25. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
26. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
Katagiri A; Nakayama K; Rahman MT; Rahman M; Katagiri H; Nakayama N; Ishikawa M; Ishibashi T; Iida K; Kobayashi H; Otsuki Y; Nakayama S; Miyazaki K
Mod Pathol; 2012 Feb; 25(2):282-8. PubMed ID: 22101352
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma.
Maeda D; Mao TL; Fukayama M; Nakagawa S; Yano T; Taketani Y; Shih IeM
Int J Mol Sci; 2010; 11(12):5120-8. PubMed ID: 21614196
[TBL] [Abstract][Full Text] [Related]
28. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
Khalique S; Naidoo K; Attygalle AD; Kriplani D; Daley F; Lowe A; Campbell J; Jones T; Hubank M; Fenwick K; Matthews N; Rust AG; Lord CJ; Banerjee S; Natrajan R
J Pathol Clin Res; 2018 Jul; 4(3):154-166. PubMed ID: 29659191
[TBL] [Abstract][Full Text] [Related]
29. Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
De Marco C; Rinaldo N; Bruni P; Malzoni C; Zullo F; Fabiani F; Losito S; Scrima M; Marino FZ; Franco R; Quintiero A; Agosti V; Viglietto G
PLoS One; 2013; 8(2):e55362. PubMed ID: 23408974
[TBL] [Abstract][Full Text] [Related]
30. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
[TBL] [Abstract][Full Text] [Related]
31. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
Samartzis EP; Gutsche K; Dedes KJ; Fink D; Stucki M; Imesch P
Oncotarget; 2014 Jul; 5(14):5295-303. PubMed ID: 24979463
[TBL] [Abstract][Full Text] [Related]
32. Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.
Zhai Y; Kuick R; Tipton C; Wu R; Sessine M; Wang Z; Baker SJ; Fearon ER; Cho KR
J Pathol; 2016 Jan; 238(1):21-30. PubMed ID: 26279473
[TBL] [Abstract][Full Text] [Related]
33. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
[TBL] [Abstract][Full Text] [Related]
34. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma.
Rahman MT; Nakayama K; Rahman M; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Cancer; 2012 Jun; 118(11):2846-57. PubMed ID: 22139760
[TBL] [Abstract][Full Text] [Related]
35. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
36. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
Goldman AR; Bitler BG; Schug Z; Conejo-Garcia JR; Zhang R; Speicher DW
Mol Cell Proteomics; 2016 Nov; 15(11):3348-3360. PubMed ID: 27654507
[TBL] [Abstract][Full Text] [Related]
37. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Jones S; Wang TL; Shih IeM; Mao TL; Nakayama K; Roden R; Glas R; Slamon D; Diaz LA; Vogelstein B; Kinzler KW; Velculescu VE; Papadopoulos N
Science; 2010 Oct; 330(6001):228-31. PubMed ID: 20826764
[TBL] [Abstract][Full Text] [Related]
38. Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma.
Ueno S; Sudo T; Oka N; Wakahashi S; Yamaguchi S; Fujiwara K; Mikami Y; Nishimura R
Int J Gynecol Cancer; 2013 Jul; 23(6):1084-91. PubMed ID: 23792604
[TBL] [Abstract][Full Text] [Related]
39. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation.
Tessier-Cloutier B; Kommoss FKF; Kolin DL; Němejcová K; Smith D; Pors J; Stewart CJR; McCluggage WG; Foulkes WD; von Deimling A; Köbel M; Lee CH
Mod Pathol; 2024 Jan; 37(1):100374. PubMed ID: 37925057
[TBL] [Abstract][Full Text] [Related]
40. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]